AC Immune (NASDAQ:ACIU) announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn trial evaluating ACI-7104.056—its anti-alpha-synuclein (a-syn) active immunotherapy candidate—for the treatment of patients with early Parkinson’s disease (PD).
According to AC Immune highlights include: active immunotherapy with ACI-7104.056 induces high anti-a-syn antibody levels on average over 20-fold higher than placebo after four immunizations; repeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titers; and ACI-7104.056 is well tolerated with no safety issues reported to date.
In a statement, Dr. Andrea Pfeifer, CEO of AC Immune, commented, “We continue to be encouraged by the data emerging from the Phase 2 VacSYn trial of ACI-7104.056 active immunotherapy in early Parkinson’s disease. These additional interim safety and immunogenicity data after 6 months of treatment underscore the good safety profile and reinforce the best-in-class characteristics of ACI-7104.056 for the treatment of Parkinson’s disease. We look forward to sharing further updates later in 2025.”
